Intro offer
100 days of Premium for just $10.
Try all Premium features for over 3 months and analyze stocks without limits.
Try 100 days for $10

$0.26
3.82%
Nasdaq, Wed, Sep 16 2026.
ISIN
US68620A1043
Symbol
ONVO

Organovo Holdings, Inc. Stock price

$0.26
-0.06 17.58% 1M
-1.54 85.44% 6M
-1.55 85.52% YTD
-3.58 93.17% 1Y
-15.58 98.35% 3Y
-87.58 99.70% 5Y
-971.74 99.97% 10Y
-5.40 95.37% 20Y
Nasdaq, Closing price Wed, Sep 16 2026
-0.01 3.82%
ISIN
US68620A1043
Symbol
ONVO
Industry

Is Organovo Holdings, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.

Key metrics

Basic
Market capitalization
$4.4m
Enterprise Value
$2.7m
Net debt
positive
Cash
$1.7m
Shares outstanding
3.2m
Valuation (TTM | estimate)
P/E
negative
P/S
39.9 | 18.6
EV/Sales
24.8 | 11.5
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-14.9%
Return on Equity
1,259.6%
ROCE
-716.0%
ROIC
-1,047.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$110.0k | $236.6k
EBITDA
$-13.8m
EBIT
$-14.0m
Net Income
$-12.3m
Free Cash Flow
$-10.1m
Growth (TTM | estimate)
Revenue
-21.4% | 82.0%
EBITDA
-16.4%
EBIT
-15.6%
Net Income
-520.1%
Free Cash Flow
2.9%
Margin
Gross
-
EBITDA
-12,357.1%
EBIT
-12,530.4%
Net
-11,016.1%
Free Cash Flow
-9,038.4%
More
EPS
$-2.4
FCF per Share
$-3.2
Short interest
4.1%
Employees
14
Rev per Employee
$10.0k

Organovo Holdings, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Organovo Holdings, Inc. forecast:

4x Hold
57%
3x Sell
43%

Analyst Opinions

7 Analysts have issued a Organovo Holdings, Inc. forecast:

Hold
57%
Sell
43%

Financial data from Organovo Holdings, Inc.

Jun '26
+/-
%
0.11 0.11
21% 21%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.12 7.12
7% 7%
6,473%
- Research and Development Expense 4.22 4.22
4% 4%
3,836%
-14 -14
16% 16%
-12,582%
- Depreciation and Amortization 0.19 0.19
27% 27%
173%
EBIT (Operating Income) EBIT -14 -14
16% 16%
-12,758%
Net Profit -12 -12
520% 520%
-11,218%

In millions USD.

Don't miss a Thing! We will send you all news about Organovo Holdings, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Organovo Holdings, Inc. engages in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company was founded on January 30, 2012 and is headquartered in San Diego, CA.

Head office United States
CEO Keith Murphy
Employees 14
Founded 2012
Website organovo.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today